Beyond Air Study Using UNO Therapy in First Patients Shows Immunostimulatory Response and Low Side Effects; Warrants Further Investigation/Data
11-6-23 (by: Scott Gleason) Beyond Air recently presented results from the first-in-human clinical data during the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023. The data showed a favorable safety profile for the company’s ultra-high concentration nitrous oxide (UNO therapy) and signs of immune system activation.
The presented data from the SITC Annual Meeting is based on the results of the first five subjects treated with 25,000 ppm UNO. The findings demonstrate that a 5-minute administration of UNO at this concentration has a notable impact on the immune system. It led . . .
Please subscribe for full access to all content. Access is free for the first month and $99 a month afterwards.